Immunovant Statistics
Share Statistics
Immunovant has 169.86M
shares outstanding. The number of shares has increased by 16.2%
in one year.
| Shares Outstanding | 169.86M |
| Shares Change (YoY) | 16.2% |
| Shares Change (QoQ) | 15.72% |
| Owned by Institutions (%) | 54.54% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,184 |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 21.4M, so 12.6% of the outstanding
shares have been sold short.
| Short Interest | 21.4M |
| Short % of Shares Out | 12.6% |
| Short % of Float | 24.46% |
| Short Ratio (days to cover) | 18.35 |
Valuation Ratios
The PE ratio is -16.83 and the forward
PE ratio is -4.71.
Immunovant's PEG ratio is
-1.69.
| PE Ratio | -16.83 |
| Forward PE | -4.71 |
| PS Ratio | 0 |
| Forward PS | 3.2 |
| PB Ratio | 7.07 |
| P/FCF Ratio | -20.34 |
| PEG Ratio | -1.69 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Immunovant.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.7,
with a Debt / Equity ratio of 0.
| Current Ratio | 13.7 |
| Quick Ratio | 13.7 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,252,830.92 |
| Employee Count | 207 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 567K |
| Effective Tax Rate | -0.22% |
Stock Price Statistics
The stock price has increased by -43.73% in the
last 52 weeks. The beta is 0.75, so Immunovant's
price volatility has been higher than the market average.
| Beta | 0.75 |
| 52-Week Price Change | -43.73% |
| 50-Day Moving Average | 15.46 |
| 200-Day Moving Average | 23.68 |
| Relative Strength Index (RSI) | 50.86 |
| Average Volume (20 Days) | 1,736,136 |
Income Statement
| Revenue | n/a |
| Gross Profit | -231K |
| Operating Income | -282.71M |
| Net Income | -259.34M |
| EBITDA | -269.98M |
| EBIT | -270.21M |
| Earnings Per Share (EPS) | -1.88 |
Full Income StatementBalance Sheet
The company has 635.37M in cash and 138K in
debt, giving a net cash position of 635.23M.
| Cash & Cash Equivalents | 635.37M |
| Total Debt | 138K |
| Net Cash | 635.23M |
| Retained Earnings | -825.68M |
| Total Assets | 420.93M |
| Working Capital | 344.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -214.23M
and capital expenditures -360K, giving a free cash flow of -214.59M.
| Operating Cash Flow | -214.23M |
| Capital Expenditures | -360K |
| Free Cash Flow | -214.59M |
| FCF Per Share | -1.55 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
